Significant Vendors (Details) - USD ($) |
3 Months Ended | 9 Months Ended | 12 Months Ended | ||||
|---|---|---|---|---|---|---|---|
Mar. 31, 2020 |
Mar. 31, 2019 |
Mar. 31, 2020 |
Mar. 31, 2019 |
Jun. 30, 2015 |
Mar. 13, 2020 |
Jun. 30, 2019 |
|
| Significant Vendor [Line Items] | |||||||
| Accounts Payable, Current | $ 547,000 | $ 547,000 | $ 1,001,000 | ||||
| Research and Development Expense | 999,000 | $ 1,453,000 | 2,864,000 | $ 3,850,000 | |||
| Revenues | 96,000 | 527,000 | 518,000 | 1,223,000 | |||
| Amended Agreement [Member] | |||||||
| Significant Vendor [Line Items] | |||||||
| Research and Development Expense | $ 2,100,000 | ||||||
| Revenues | 0 | ||||||
| Fraunhofer [Member] | |||||||
| Significant Vendor [Line Items] | |||||||
| Accounts Payable, Current | $ 75,000 | 75,000 | |||||
| Novici [Member] | |||||||
| Significant Vendor [Line Items] | |||||||
| Accounts Payable, Current | 0 | 0 | $ 65,000 | ||||
| Research and Development Expense | $ 0 | $ 217,000 | $ 97,000 | $ 761,000 | |||
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|